Beta Bionics, Inc.

BBNX Nasdaq SEC CIK 1674632
Follow Beta Bionics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $35.5M +30.3% vs same quarter last year
Net income −$24.4M −71.4% vs same quarter last year
EPS, diluted −$0.52 −57.6% vs same quarter last year
Operating cash flow −$12.3M −40.8% vs same quarter last year
Revenue by quarter
$20.4M
$17.6M
$23.2M
$27.3M
$32.1M
$27.6M
$32M
$35.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100M$150MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$100.3M−$73.2M
FY24$65.1M−$54.8M
FY23$12M−$44.1M
FY22--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2555.4%−71.5%−73%
FY2455.1%−69.5%−84.1%
FY2352.6%−298.9%−367.6%
FY22---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$56.2M
FY24−$51.7M
FY23−$32.8M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Beta Bionics
  • Healthcare median
−400%−300%−200%−100%0%FY22FY23FY24FY25
Show the numbers
YearBeta BionicsHealthcare median
FY25−73%−30.6%
FY24−84.1%−47%
FY23−367.6%−58%
FY22-−80.4%